000156763 001__ 156763
000156763 005__ 20240229123115.0
000156763 0247_ $$2doi$$a10.1186/s40478-020-00978-7
000156763 0247_ $$2pmid$$apmid:32605662
000156763 0247_ $$2altmetric$$aaltmetric:85024553
000156763 037__ $$aDKFZ-2020-01087
000156763 041__ $$aeng
000156763 082__ $$a610
000156763 1001_ $$aAppay, Romain$$b0
000156763 245__ $$aDiffuse leptomeningeal glioneuronal tumor: a double misnomer? A report of two cases.
000156763 260__ $$aLondon$$bBiomed Central$$c2020
000156763 3367_ $$2DRIVER$$aarticle
000156763 3367_ $$2DataCite$$aOutput Types/Journal article
000156763 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1593773792_29721
000156763 3367_ $$2BibTeX$$aARTICLE
000156763 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000156763 3367_ $$00$$2EndNote$$aJournal Article
000156763 520__ $$aDiffuse leptomeningeal glioneuronal tumor (DLGNT) was introduced, for the first time, as a provisional entity in the 2016 WHO classification of central nervous system tumors. DLGNT mainly occur in children and characterized by a widespread leptomeningeal growth occasionally associated with intraspinal tumor nodules, an oligodendroglial-like cytology, glioneuronal differentiation and MAP-Kinase activation associated with either solitary 1p deletion or 1p/19q codeletion in the absence of IDH mutation.We report here two unexpected DLGNTs adult cases, characterized by a unique supratentorial circumscribed intraparenchymal tumor without leptomeningeal involvement in spite of long follow-up. In both cases, the diagnosis of DLGNT was made after DNA-methylation profiling which demonstrated that one case belonged to the DLGNT class whereas the other remained not classifiable but showed on CNV the characteristic genetic findings recorded in DLGNT. Both cases harbored 1p/19q codeletion associated with KIAA1549:BRAF fusion in one case and with BRAF V600E and PIK3CA E545A mutations, in the other.Our study enlarges the clinical and molecular spectrum of DLGNTs, and points out that the terminology of DLGNTs is not fully appropriate since some cases could have neither diffuse growth nor leptomeningeal dissemination. This suggests that DLGNTs encompass a wide spectrum of tumors that has yet to be fully clarified.
000156763 536__ $$0G:(DE-HGF)POF3-312$$a312 - Functional and structural genomics (POF3-312)$$cPOF3-312$$fPOF III$$x0
000156763 588__ $$aDataset connected to CrossRef, PubMed,
000156763 7001_ $$aPages, Mélanie$$b1
000156763 7001_ $$aColin, Carole$$b2
000156763 7001_ $$0P:(DE-He78)551bb92841f634070997aa168d818492$$aJones, David T W$$b3$$udkfz
000156763 7001_ $$aVarlet, Pascale$$b4
000156763 7001_ $$00000-0002-3604-887X$$aFigarella-Branger, Dominique$$b5
000156763 773__ $$0PERI:(DE-600)2715589-4$$a10.1186/s40478-020-00978-7$$gVol. 8, no. 1, p. 95$$n1$$p95$$tActa Neuropathologica Communications$$v8$$x2051-5960$$y2020
000156763 909CO $$ooai:inrepo02.dkfz.de:156763$$pVDB
000156763 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)551bb92841f634070997aa168d818492$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000156763 9131_ $$0G:(DE-HGF)POF3-312$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunctional and structural genomics$$x0
000156763 9141_ $$y2020
000156763 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bACTA NEUROPATHOL COM : 2018$$d2020-01-09
000156763 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2020-01-09
000156763 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-01-09
000156763 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database$$d2020-01-09
000156763 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2020-01-09
000156763 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2020-01-09
000156763 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2020-01-09
000156763 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2020-01-09
000156763 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2020-01-09
000156763 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2020-01-09
000156763 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2020-01-09
000156763 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-01-09
000156763 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-01-09
000156763 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-01-09
000156763 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-01-09
000156763 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2020-01-09
000156763 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2020-01-09
000156763 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bACTA NEUROPATHOL COM : 2018$$d2020-01-09
000156763 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$f2020-01-09
000156763 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2020-01-09
000156763 9201_ $$0I:(DE-He78)B360-20160331$$kB360$$lPediatric Glioma$$x0
000156763 980__ $$ajournal
000156763 980__ $$aVDB
000156763 980__ $$aI:(DE-He78)B360-20160331
000156763 980__ $$aUNRESTRICTED